SCOPUS 정보 검색 플랫폼

Ophthalmology

Volumn 120, Issue 5 SUPPL., 2013, Pages

Neovascular age-related macular degeneration: Individualizing therapy in the era of anti-angiogenic treatments

(1) Heier, Jeffrey S a

a OPHTHALMIC CONSULTANTS OF BOSTON (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; INDOCYANINE GREEN; RANIBIZUMAB;

CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; NOTE; PATIENT CARE; PATIENT MONITORING; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISION;

EID: 84876988920 PISSN: 01616420 EISSN: 15494713 Source Type: Journal
DOI: 10.1016/j.ophtha.2013.01.059 Document Type: Article

Times cited : (8)

References (6)

1
- 38349172455
- Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
- C.D. Regillo, D.M. Brown, P. Abraham Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
- (2008) Am J Ophthalmol , vol.145 , pp. 239-248
- Regillo, C.D.¹ Brown, D.M.² Abraham, P.³

2
- 77956056292
- Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2
- e311
- P. Abraham, H. Yue, L. Wilson Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 Am J Ophthalmol 150 2010 315 324 e311
- (2010) Am J Ophthalmol , vol.150 , pp. 315-324
- Abraham, P.¹ Yue, H.² Wilson, L.³

3
- 79955631484
- Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study
- U. Schmidt-Erfurth, B. Eldem, R. Guymer Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 2011 831 839
- (2011) Ophthalmology , vol.118 , pp. 831-839
- Schmidt-Erfurth, U.¹ Eldem, B.² Guymer, R.³

4
- 67149101784
- A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study
- e41
- G.A. Lalwani, P.J. Rosenfeld, A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58 e41
- (2009) Am J Ophthalmol , vol.148 , pp. 43-58
- Lalwani, G.A.¹ Rosenfeld, P.J.² Fung, A.E.³

5
- 69249222585
- A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration
- D.S. Boyer, J.S. Heier, D.M. Brown A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
- (2009) Ophthalmology , vol.116 , pp. 1731-1739
- Boyer, D.S.¹ Heier, J.S.² Brown, D.M.³

6
- 84870723704
- Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration
- J.S. Heier, D.M. Brown, V. Chong Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
- (2012) Ophthalmology , vol.119 , pp. 2537-2548
- Heier, J.S.¹ Brown, D.M.² Chong, V.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.